GLP-1 receptors

Brenipatide is a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the gastric inhibitory polypeptide (GIP) receptor. It is primarily utilized in researching metabolic disorders, obesity, and diabetes, demonstrating significant potential in enhancing insulin secretion and promoting weight loss. This compound is essential for studies investigating the pathways and mechanisms involved in glucose homeostasis and energy balance.

Utreglutide is a potent glucagon-like peptide-1 (GLP-1) receptor agonist that plays a significant role in the regulation of glucose metabolism. This compound not only aids in lowering blood pressure and blood lipid levels but also contributes to weight reduction and enhances cardiovascular health. Utreglutide is particularly valuable in research focusing on type 2 diabetes and obesity-related conditions, facilitating a deeper understanding of metabolic disorders.

CHU-128 is a selective GLP-1 receptor (GLP-1R) agonist that effectively activates the Gs/cAMP signaling pathway. This compound is characterized by its strong signal specificity, as it does not engage the Gq/calcium signaling pathway, ERK phosphorylation, or recruit β-inhibitory proteins. CHU-128 is suitable for research applications focused on type 2 diabetes and related metabolic disorders.

GLP-1R agonist 39 is a potent positive allosteric modulator of the GLP-1 receptor. This compound enhances the activity of the GLP-1 receptor, making it valuable for studies related to obesity and type 2 diabetes. Its application in research enables the exploration of therapeutic strategies aimed at metabolic disorders.

GLP-1R agonist 38 is a selective agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound exhibits significant biological activity in enhancing insulin secretion, suppressing glucagon release, and promoting weight reduction, making it a valuable tool for studying metabolic disorders. It is applicable in research related to type II diabetes mellitus (T2DM), obesity, and non-alcoholic fatty liver disease (NASH).

GLP-1 Receptor Agonist 18 is a potent GLP-1 receptor agonist with an EC50 of 0.22 nM. This compound demonstrates significant biological activity by lowering blood glucose levels and promoting weight loss, making it valuable for diabetes research. Its efficacy in modulating GLP-1 receptor signaling positions it as a useful tool for investigating therapeutic strategies in metabolic disorders.

GLP-1R agonist 26 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of less than 10 nM. This compound plays a crucial role in enhancing insulin secretion, promoting weight loss, and exhibiting cardioprotective effects. It is primarily utilized in research focused on metabolic disorders, diabetes, and obesity treatment.

GLP-1R agonist 29 is a potent agonist of the GLP-1 receptor, effectively stimulating cAMP production with an EC50 value of 0.018 nM. This compound demonstrates favorable pharmacokinetic properties, evidenced by a robust body exposure reflected in an AUC0-∞,sc of 77688 ng·h/mL. It serves as a valuable tool for research applications related to metabolic disorders and diabetes, allowing for exploration of GLP-1R signaling pathways.

GLP-1R Agonist 25 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.167 nM. This compound plays a crucial role in stimulating insulin secretion and regulating glucose metabolism, making it a valuable tool for research focused on type II diabetes and related metabolic disorders. Its potent biological activity supports the exploration of therapeutic strategies aimed at improving glycemic control.

AZ13581837 is a potent GPR120 agonist, demonstrating human and mouse EC50 values of 5.2 nM and 4.3 nM, respectively. This compound activates Gαq, Gαs, and β-arrestin signaling pathways, effectively reducing cAMP levels, stimulating GLP-1 secretion, promoting glucose lowering, and enhancing insulin secretion. AZ13581837 is valuable for research related to type 2 diabetes, providing insights into potential therapeutic strategies targeting metabolic disorders.

AS1269574 is a potent agonist of GPR119, exhibiting an EC50 of 2.5 μM in HEK293 cells expressing the human receptor. This compound activates TRPA1 cation channels, thereby facilitating the secretion of glucagon-like peptide-1 (GLP-1). Notably, AS1269574 induces glucose-dependent insulin secretion from pancreatic β-cells exclusively under high-glucose conditions, making it a valuable tool for research into type 2 diabetes.

K-833 is a potent GPR119 agonist with EC50 values of 39.8 nM in humans, 100 nM in mice, 75.4 nM in rats, and 12.6 nM in dogs. This compound enhances GLP-1 secretion and exhibits a synergistic effect on GLP-1 levels when administered alongside AM-5262 in acute gut peptide secretion assays in mice. K-833 is suitable for research focusing on weight loss and metabolic regulation.

Elobixibat hydrate is an orally active inhibitor of the intestinal bile acid transporter (IBAT), demonstrating potent activity with IC50 values of 0.53 nM for human IBAT, 0.13 nM for mouse IBAT, and 5.8 nM for canine IBAT. This compound has been shown to effectively lower LDL cholesterol levels, enhance serum GLP-1 concentrations, and promote colonic motility. Elobixibat hydrate is valuable for research applications related to chronic idiopathic constipation (CIC), dyslipidemia, non-alcoholic fatty liver disease, and the study of liver tumors, particularly in elderly populations.

DMG-PEG is a lipid compound that enhances the hydrophilicity and electrical neutrality of lPEI/DNA nanoparticles, facilitating improved transport and diffusivity in the gastrointestinal mucus layer. This pegylated lipid is pivotal in formulating liposomes for siRNA delivery, significantly increasing transfection efficiency. In vivo studies demonstrate that nucleic acid nanoparticles coated with DMG-PEG effectively maintain elevated levels of glucagon-like peptide-1 (GLP-1) expression in liver, lung, and intestinal tissues of type II diabetic mouse models, while also regulating blood glucose levels. Additionally, DMG-PEG serves as an effective component in the preparation of lipid nanoparticles for mRNA therapeutics.

Colesevelam hydrochloride is a bile acid sequestrant that primarily acts by binding bile acids in the gastrointestinal tract, leading to the formation of nonabsorbable complexes. This action interrupts enterohepatic recirculation and enhances fecal bile acid elimination. In addition to lowering lipids, colesevelam modulates FXR, TGR5, and CYP7A1 activities, which in turn activates cAMP signaling and promotes GLP-1 release. Its applications in research include investigations into type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease, while also influencing hepatic lipid and glucose metabolism.

5-OAHSA is an endogenous metabolite that functions as a lipid mediator. It is known to lower blood glucose levels, enhance glucose tolerance, and stimulate the secretion of glucagon-like peptide-1 (GLP-1) and insulin. 5-OAHSA is valuable for research applications focused on metabolic regulation and inflammation modulation.

H-Lys(Fmoc)-OH hydrochloride is an amino acid derivative featuring an Fmoc protecting group. This compound serves as a key intermediate for the synthesis of diacylated GLP-1 derivatives, which possess antidiabetic properties. Its utility in peptide synthesis makes it an important reagent in chemical biology and drug development.

Pinolenic acid ethyl ester is a derivative of pinolenic acid, a polyunsaturated fatty acid known for its lipid-regulating properties. This reagent is used in biochemical assays to study appetite regulation and lipid metabolism due to its ability to enhance satiety hormone levels such as CCK and GLP-1, contributing to appetite suppression. Research indicates that pinolenic acid can diminish arachidonic acid levels in hepatic cells, making it relevant for studies investigating cholesterol efflux and fatty acid metabolism. Its lipophilic nature allows for versatile applications in various biochemical studies targeting metabolic pathways.

Fmoc-Lys(tBuO-Ara-Glu(AEEA-AEEA)-OtBu)-OH is a key drug intermediate in the synthesis of Tirzepatide, which functions as a dual agonist of the glucose-dependent insulinotropic peptide (GIP) and the glucagon-like peptide-1 receptor (GLP-1R). This compound is essential for research and development in diabetes therapeutics, as Tirzepatide enhances insulin secretion and improves glycemic control. Its structural features facilitate the exploration of peptide-based treatments for metabolic disorders.

(D-Asp28)-Exenatide is an impurity of Exenatide, which functions as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. This compound plays a significant role in the regulation of glucose homeostasis and appetite control, making it relevant for research in diabetes and obesity. The characterization of this impurity is essential for understanding the pharmacological properties and ensuring the quality of Exenatide in therapeutic applications.

Semaglutide Main Chain (9-37) serves as a peptide starting material for the synthesis of the semaglutide prodrug. This compound is integral in facilitating the development of semaglutide, which is a GLP-1 receptor agonist known for its role in enhancing glucose-dependent insulin secretion and reducing appetite. It is widely applicable in diabetes research and therapeutic development aimed at metabolic disorders.

GLP-1R Agonist 3 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound, a modified imidazole derivative, plays a significant role in modulating insulin secretion and glucose homeostasis. GLP-1R Agonist 3 is primarily utilized in research focused on diabetes and metabolic disorders, offering avenues for developing novel therapeutic strategies.